Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Athenex.

Community Practice Connections™: Integrating Oral Chemotherapy Formulations in Breast Cancer Care

Release Date: September 1, 2020
Expiration Date: September 1, 2021

Activity Overview

Chemotherapy has been the foundation of breast cancer care for decades, with great impact on survival outcomes with combination chemotherapy, dose-dense chemotherapy, and metronomic chemotherapy regimens. These benefits come at a price, however, with adverse events, such as infusion-related reactions, peripheral neuropathy, and alopecia, that are associated with intravenous administration of these drugs. Even with all the advancements in other classes of drugs for treating breast cancer, chemotherapy remains the mainstay. The time has come for the development of innovative platforms for convenient oral chemotherapy delivery that allow for the continued use of these agents with improved safety profiles and better quality of life for patients.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the Oncology Best Practice™ regional series on integrating oral chemotherapy formulations in breast cancer care held in 2020. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with advanced breast cancer, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meetings and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Athenex.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This activity is directed toward medical, surgical, and radiation oncologists who treat or manage patients with breast cancer. Fellows, nurses, nurse practitioners, physician assistants, researchers, pharmacists, and other healthcare professionals interested in the treatment or management of these tumors are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Discuss that rationale supporting the role of oral chemotherapeutic formulations in the treatment of patients with breast cancer
  • Review data from recent clinical trials evaluating efficacy and safety of oral chemotherapeutic formulations in breast cancer treatment
  • Examine strategies for optimizing treatment outcomes and patient selection for oral chemotherapeutic regimens
  • Discuss effective strategies to proactively counsel and manage adverse events associated with chemotherapy in the treatment of patients with breast cancer

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Charles G. Drake, MD, PhD, FAAP
Hope S. Rugo, MD, FASCO
Professor of Medicine, Director, Breast Oncology and Clinical Trials Education
University of California / Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Disclosures: Grant/Research Support: Daiichi, Eisai, Genentech, Immunomedics, Lilly, Macrogenics, Merck, Novartis, OBI, Odonate, Pfizer, and Seattle Genetics. Consultant: Celtrion and Ionis Pharma.

Johanna Bendell, MD
Shayma Kazmi, MD
Hematologist/Oncologist/Internal Medicine
Cancer Treatment Centers of America
Philadelphia, PA

Disclosures: Grant/Research Support: Merck, POMS. Consultant: Eisai, Immunomedics, Lilly, Merck, and Takeda. Speaker’s Bureau: Eisai, Immunomedics, Lilly, Merck, and Takeda. Stock/ Shareholder: Lilly, Merck.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By